Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

ABSTRACT:

Background

Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD.

Methods

One hundred thirty-one participants (sertraline = 67, placebo = 64) with mild-moderate AD and depression participated in the study. Patients who showed improvement on the modified Alzheimer's Disease Cooperative Study Clinical Global Impression-Change (mADCS-CGIC) after 12 weeks of randomized treatment with sertraline or placebo continued double-blinded treatment for an additional 12 weeks. Depression response and remission at 24 weeks were based on mADCS-CGIC sc

SUBMITTER: Weintraub D 

PROVIDER: S-EPMC2849739 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature